Research & Development

Lilly Pushes Jaypirca for Wider Use in Leukemia at ASH
Research & Development Lilly Pushes Jaypirca for Wider Use in Leukemia at ASH

Imagine a world where a single drug could shift the trajectory of blood cancer treatment, offering hope to thousands battling chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). At the recent American Society of Hematology (ASH) meeting in Orlando, Eli Lilly thrust its BTK

Can Casgevy Transform Lives of Kids with Blood Disorders?
Research & Development Can Casgevy Transform Lives of Kids with Blood Disorders?

Allow me to introduce Ivan Kairatov, a seasoned biopharma expert whose extensive background in technology and innovation has positioned him at the forefront of groundbreaking developments in genetic medicine. With years of experience in research and development, Ivan has been closely following the

NeuMap Immune Mapping Technology – Review
Research & Development NeuMap Immune Mapping Technology – Review

Imagine a world where the most abundant immune cells in the human body, crucial for fighting infections, remain a mysterious black box to scientists and medical professionals. For too long, neutrophils—those rapid-response warriors of the immune system—have been just that, with their complex

Rethinking Aging: Beyond Hallmarks and Current Measures
Research & Development Rethinking Aging: Beyond Hallmarks and Current Measures

Imagine a world where living to 100 is common, yet the decline of mind and body feels just as relentless as it does today—where longer life doesn’t mean slower aging. This paradox lies at the heart of a provocative critique by Dr. Dan Ehninger and Dr. Maryam Keshavarz, published in Genomic

New Strategy Boosts Immunotherapy in ER-Positive Breast Cancer
Research & Development New Strategy Boosts Immunotherapy in ER-Positive Breast Cancer

What if the key to beating the most common type of breast cancer lay hidden in the body's own defenses, waiting for science to unlock its potential? For the millions of women diagnosed with estrogen receptor-positive (ER-positive) breast cancer, which accounts for about 70% of all cases, a new

Why Are Ex-FDA Chiefs Opposing New Vaccine Standards?
Research & Development Why Are Ex-FDA Chiefs Opposing New Vaccine Standards?

What happens when the very architects of public health safety turn against their own system, warning of a dangerous shift that could jeopardize millions of lives? Twelve former FDA commissioners, a powerhouse of regulatory wisdom, have ignited a firestorm by publicly condemning proposed changes to

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later